Global Automated Insulin Delivery (AID) Market: Size & Forecast with Impact Analysis of COVID-19 (2020-2024)
SCOPE OF THE REPORT
The report titled “Global Automated Insulin Delivery (AID) Market: Size & Forecast with Impact Analysis of COVID-19 (2020-2024)”, provides an in-depth analysis of the global automated insulin delivery (AID) market with description of market sizing and growth. Furthermore, the report also provides detailed analysis of market by value, by device, by diabetes, by end user and by region.
Moreover, the report also assesses the key opportunities in the market and outlines the factors that are and would be driving the growth of the industry. Growth of the overall global automated insulin delivery (AID) market has also been forecasted for the years 2020-2024, taking into consideration the previous growth patterns, the growth drivers and the current and future trends.
Some of the major players operating in the global automated insulin delivery (AID) market are Medtronic Plc, Eli Lilly and Company, Novo Nordisk and Biocon, whose company profiling has been done in the report. Furthermore, in this segment of the report, business overview, financial overview and business strategies of the respective companies are also provided.
Region Coverage
Automated insulin delivery (AID) is also known as hybrid or full closed loop, artificial pancreas system (APS), looping, etc. Automated insulin delivery (AID) is a method for managing diabetes but it is not same for every patient. Patients have choices, ranging from the type of insulin pump and continuous glucose monitor (CGM) patient want to use. In addition, the technology has advanced the regulation of blood glucose concentrations, minimized the frequency of hyperglycaemic and improved the quality of life of people with diabetes.
There are different algorithms which are proposed for artificial pancreas system, which includes proportional integral derivative (PID) algorithms, model predictive control (MPC) algorithms and fuzzy logic algorithms.
Moreover, on the basis of devices automated insulin delivery (AID) can be segmented into hybrid closed loop and fully closed loop devices, whereas on the basis of end user automated insulin delivery (AID) can be bifurcated into hospital, retail medical store, health center and other.
The global automated insulin delivery (AID) market has progressed promptly over the years and the market is further anticipated to escalate during the forecasted years 2020 to 2024. The market would augment owing to numerous growth drivers such as, increasing diabetic population, growth in geriatric population, rising global healthcare expenditure, surging obese population, change in lifestyle of people globally, etc.
However, the market faces some challenges which are hindering the growth of the market. Some of the major challenges faced by the industry are: oral insulin and regulatory compliance problem. Moreover, the market growth would also succeed by various market trends like rising adoption of wearable healthcare devices and novel product launches.
The report titled “Global Automated Insulin Delivery (AID) Market: Size & Forecast with Impact Analysis of COVID-19 (2020-2024)”, provides an in-depth analysis of the global automated insulin delivery (AID) market with description of market sizing and growth. Furthermore, the report also provides detailed analysis of market by value, by device, by diabetes, by end user and by region.
Moreover, the report also assesses the key opportunities in the market and outlines the factors that are and would be driving the growth of the industry. Growth of the overall global automated insulin delivery (AID) market has also been forecasted for the years 2020-2024, taking into consideration the previous growth patterns, the growth drivers and the current and future trends.
Some of the major players operating in the global automated insulin delivery (AID) market are Medtronic Plc, Eli Lilly and Company, Novo Nordisk and Biocon, whose company profiling has been done in the report. Furthermore, in this segment of the report, business overview, financial overview and business strategies of the respective companies are also provided.
Region Coverage
- Asia Pacific
- North America
- Europe
- Latin America
- Middle East & Africa
- Medtronic Plc
- Eli Lilly and Company
- Novo Nordisk
- Biocon
Automated insulin delivery (AID) is also known as hybrid or full closed loop, artificial pancreas system (APS), looping, etc. Automated insulin delivery (AID) is a method for managing diabetes but it is not same for every patient. Patients have choices, ranging from the type of insulin pump and continuous glucose monitor (CGM) patient want to use. In addition, the technology has advanced the regulation of blood glucose concentrations, minimized the frequency of hyperglycaemic and improved the quality of life of people with diabetes.
There are different algorithms which are proposed for artificial pancreas system, which includes proportional integral derivative (PID) algorithms, model predictive control (MPC) algorithms and fuzzy logic algorithms.
Moreover, on the basis of devices automated insulin delivery (AID) can be segmented into hybrid closed loop and fully closed loop devices, whereas on the basis of end user automated insulin delivery (AID) can be bifurcated into hospital, retail medical store, health center and other.
The global automated insulin delivery (AID) market has progressed promptly over the years and the market is further anticipated to escalate during the forecasted years 2020 to 2024. The market would augment owing to numerous growth drivers such as, increasing diabetic population, growth in geriatric population, rising global healthcare expenditure, surging obese population, change in lifestyle of people globally, etc.
However, the market faces some challenges which are hindering the growth of the market. Some of the major challenges faced by the industry are: oral insulin and regulatory compliance problem. Moreover, the market growth would also succeed by various market trends like rising adoption of wearable healthcare devices and novel product launches.
1. EXECUTIVE SUMMARY
2. INTRODUCTION
2.1 Insulin Delivery Devices: An Overview
2.2 Different Insulin Delivery Devices
2.3 Automated Insulin Delivery Devices: An Overview
2.4 Important Algorithms Proposed for Artificial Pancreas System
2.5 Comparison of MPC, PID, and Fuzzy-Logic Algorithms
2.6 Automated Insulin Delivery Segmentation
3. GLOBAL MARKET ANALYSIS
3.1 Global Automated Insulin Delivery (AID) Market: An Analysis
3.1.1 Global Automated Insulin Delivery (AID) Market by Value
3.1.2 Global Automated Insulin Delivery (AID) Market by Device (Hybrid Closed Loop and Fully Closed Loop)
3.1.3 Global Automated Insulin Delivery (AID) Market by Diabetes (Type I Diabetes and Type II Diabetes)
3.1.4 Global Automated Insulin Delivery (AID) Market by End-User (Hospital, Retail Medical Store, Health Center and Other)
3.1.5 Global Automated Insulin Delivery (AID) Market by Region (North America, Europe, Asia Pacific, Latin America and Middle East & Africa)
3.2 Global Automated Insulin Delivery (AID) Market: Device Analysis
3.2.1 Global Hybrid Closed Loop AID Market by Value
3.2.2 Global Fully Closed Loop AID Market by Value
3.3 Global Automated Insulin Delivery (AID) Market: Diabetes Analysis
3.3.1 Global Automated Insulin Delivery (AID) Type I Diabetes Market by Value
3.3.2 Global Automated Insulin Delivery (AID) Type II Diabetes Market by Value
3.4 Global Automated Insulin Delivery (AID) Market: End-User Analysis
3.4.1 Global Hospital Automated Insulin Delivery (AID) Market by Value
3.4.2 Global Retail Medical Store Automated Insulin Delivery (AID) Market by Value
3.4.3 Global Health Centre Automated Insulin Delivery (AID) Market by Value
4. REGIONAL MARKET ANALYSIS
4.1 North America Automated Insulin Delivery (AID) Market: An Analysis
4.1.1 North America Automated Insulin Delivery (AID) Market by Value
4.1.2 North America Automated Insulin Delivery (AID) Market by Device
4.1.3 North America Hybrid Closed Loop AID Market by Value
4.1.4 North America Fully Closed Loop AID Market by Value
4.1.5 North America Automated Insulin Delivery (AID) Market by Diabetes
4.1.6 North America Automated Insulin Delivery (AID) Type I Diabetes Market by Value
4.1.7 North America Automated Insulin Delivery (AID) Type II Diabetes Market by Value
4.1.8 North America Automated Insulin Delivery (AID) Market by End User
4.1.9 North America Hospital Automated Insulin Delivery (AID) Market by Value
4.1.10 North America Retail Medical Store Automated Insulin Delivery (AID) Market by Value
4.1.11 North America Health Centre Automated Insulin Delivery (AID) Market by Value
4.1.12 North America Automated Insulin Delivery (AID) Market by Countries
4.1.13 The US Automated Insulin Delivery (AID) Market by Value
4.1.14 Canada Automated Insulin Delivery (AID) Market by Value
4.2 Europe Automated Insulin Delivery (AID) Market: An Analysis
4.2.1 Europe Automated Insulin Delivery (AID) Market by Value
4.2.2 Europe Automated Insulin Delivery (AID) Market by Devices
4.2.3 Europe Hybrid Closed Loop AID Market by Value
4.2.4 Europe Fully Closed Loop AID Market by Value
4.2.5 Europe Automated Insulin Delivery (AID) Market by Diabetes
4.2.6 Europe Automated Insulin Delivery (AID) Type I Diabetes Market by Value
4.2.7 Europe Automated Insulin Delivery (AID) Type II Diabetes Market by Value
4.2.8 Europe Automated Insulin Delivery (AID) Market by End User
4.2.9 Europe Hospital Automated Insulin Delivery (AID) Market by Value
4.2.10 Europe Retail Medical Store Automated Insulin Delivery (AID) Market by Value
4.2.11 Europe Health Centre Automated Insulin Delivery (AID) Market by Value
4.2.12 Europe Automated Insulin Delivery (AID) Market by Countries
4.2.13 Germany Automated Insulin Delivery (AID) Market by Value
4.2.14 France Automated Insulin Delivery (AID) Market by Value
4.2.15 UK Automated Insulin Delivery (AID) Market by Value
4.2.16 Italy Automated Insulin Delivery (AID) Market by Value
4.2.17 Spain Automated Insulin Delivery (AID) Market by Value
4.3 Asia Pacific Automated Insulin Delivery (AID) Market: An Analysis
4.3.1 Asia Pacific Automated Insulin Delivery (AID) Market by Value
4.3.2 Asia Pacific Automated Insulin Delivery (AID) Market by Devices
4.3.3 Asia Pacific Hybrid Closed Loop AID Market by Value
4.3.4 Asia Pacific Fully Closed Loop AID Market by Value
4.3.5 Asia Pacific Automated Insulin Delivery (AID) Market by Diabetes
4.3.6 Asia Pacific Automated Insulin Delivery (AID) Type I Diabetes Market by Value
4.3.7 Asia Pacific Automated Insulin Delivery (AID) Type II Diabetes Market by Value
4.3.8 Asia Pacific Automated Insulin Delivery (AID) Market by End User
4.3.9 Asia Pacific Hospital Automated Insulin Delivery (AID) Market by Value
4.3.10 Asia Pacific Retail Medical Store Automated Insulin Delivery (AID) Market by Value
4.3.11 Asia Pacific Health Centre Automated Insulin Delivery (AID) Market by Value
4.3.12 Asia Pacific Automated Insulin Delivery (AID) Market by Countries
4.3.13 Japan Automated Insulin Delivery (AID) Market by Value
4.3.14 China Automated Insulin Delivery (AID) Market by Value
4.3.15 India Automated Insulin Delivery (AID) Market by Value
4.3.16 Australia Automated Insulin Delivery (AID) Market by Value
4.3.17 South Korea Automated Insulin Delivery (AID) Market by Value
4.4 Latin America Automated Insulin Delivery (AID) Market: An Analysis
4.4.1 Latin America Automated Insulin Delivery (AID) Market by Value
4.5 Middle East & Africa Automated Insulin Delivery (AID) Market: An Analysis
4.5.1 Middle East & Africa Automated Insulin Delivery (AID) Market by Value
5. COVID-19
5.1 Impact of Covid-19
5.2 Response of Industry to Covid-19
5.3 Variation in Organic Traffic
6. MARKET DYNAMICS
6.1 Growth Drivers
6.1.1 Increasing Diabetic Population
6.1.2 Growth in Geriatric Population
6.1.3 Surging Obese Population
6.1.4 Rising Global Healthcare Expenditure
6.1.5 Change in Lifestyle
6.2 Challenges
6.2.1 Oral Insulin
6.2.2 Regulatory Compliance Problem
6.3 Market Trends
6.3.1 Rising Adoption of Wearable Healthcare Devices
6.3.2 Novel Product Launches
7. COMPETITIVE LANDSCAPE
7.1 Global Automated Insulin Delivery (AID) Market Players: A Financial Comparison
7.2 Global Insulin Pump Installed Base Unit Market Share by Players
7.3 Global Insulin Pump Sales Market Share by Players
8. COMPANY PROFILES
8.1 Novo Nordisk
8.1.1 Business Overview
8.1.2 Financial Overview
8.1.3 Business Strategy
8.2 Medtronic Plc
8.2.1 Business Overview
8.2.2 Financial Overview
8.2.3 Business Strategy
8.3 Biocon
8.3.1 Business Overview
8.3.2 Financial Overview
8.3.3 Business Strategy
8.4 Eli Lilly and Company
8.4.1 Business Overview
8.4.2 Financial Overview
8.4.3 Business Strategy
2. INTRODUCTION
2.1 Insulin Delivery Devices: An Overview
2.2 Different Insulin Delivery Devices
2.3 Automated Insulin Delivery Devices: An Overview
2.4 Important Algorithms Proposed for Artificial Pancreas System
2.5 Comparison of MPC, PID, and Fuzzy-Logic Algorithms
2.6 Automated Insulin Delivery Segmentation
3. GLOBAL MARKET ANALYSIS
3.1 Global Automated Insulin Delivery (AID) Market: An Analysis
3.1.1 Global Automated Insulin Delivery (AID) Market by Value
3.1.2 Global Automated Insulin Delivery (AID) Market by Device (Hybrid Closed Loop and Fully Closed Loop)
3.1.3 Global Automated Insulin Delivery (AID) Market by Diabetes (Type I Diabetes and Type II Diabetes)
3.1.4 Global Automated Insulin Delivery (AID) Market by End-User (Hospital, Retail Medical Store, Health Center and Other)
3.1.5 Global Automated Insulin Delivery (AID) Market by Region (North America, Europe, Asia Pacific, Latin America and Middle East & Africa)
3.2 Global Automated Insulin Delivery (AID) Market: Device Analysis
3.2.1 Global Hybrid Closed Loop AID Market by Value
3.2.2 Global Fully Closed Loop AID Market by Value
3.3 Global Automated Insulin Delivery (AID) Market: Diabetes Analysis
3.3.1 Global Automated Insulin Delivery (AID) Type I Diabetes Market by Value
3.3.2 Global Automated Insulin Delivery (AID) Type II Diabetes Market by Value
3.4 Global Automated Insulin Delivery (AID) Market: End-User Analysis
3.4.1 Global Hospital Automated Insulin Delivery (AID) Market by Value
3.4.2 Global Retail Medical Store Automated Insulin Delivery (AID) Market by Value
3.4.3 Global Health Centre Automated Insulin Delivery (AID) Market by Value
4. REGIONAL MARKET ANALYSIS
4.1 North America Automated Insulin Delivery (AID) Market: An Analysis
4.1.1 North America Automated Insulin Delivery (AID) Market by Value
4.1.2 North America Automated Insulin Delivery (AID) Market by Device
4.1.3 North America Hybrid Closed Loop AID Market by Value
4.1.4 North America Fully Closed Loop AID Market by Value
4.1.5 North America Automated Insulin Delivery (AID) Market by Diabetes
4.1.6 North America Automated Insulin Delivery (AID) Type I Diabetes Market by Value
4.1.7 North America Automated Insulin Delivery (AID) Type II Diabetes Market by Value
4.1.8 North America Automated Insulin Delivery (AID) Market by End User
4.1.9 North America Hospital Automated Insulin Delivery (AID) Market by Value
4.1.10 North America Retail Medical Store Automated Insulin Delivery (AID) Market by Value
4.1.11 North America Health Centre Automated Insulin Delivery (AID) Market by Value
4.1.12 North America Automated Insulin Delivery (AID) Market by Countries
4.1.13 The US Automated Insulin Delivery (AID) Market by Value
4.1.14 Canada Automated Insulin Delivery (AID) Market by Value
4.2 Europe Automated Insulin Delivery (AID) Market: An Analysis
4.2.1 Europe Automated Insulin Delivery (AID) Market by Value
4.2.2 Europe Automated Insulin Delivery (AID) Market by Devices
4.2.3 Europe Hybrid Closed Loop AID Market by Value
4.2.4 Europe Fully Closed Loop AID Market by Value
4.2.5 Europe Automated Insulin Delivery (AID) Market by Diabetes
4.2.6 Europe Automated Insulin Delivery (AID) Type I Diabetes Market by Value
4.2.7 Europe Automated Insulin Delivery (AID) Type II Diabetes Market by Value
4.2.8 Europe Automated Insulin Delivery (AID) Market by End User
4.2.9 Europe Hospital Automated Insulin Delivery (AID) Market by Value
4.2.10 Europe Retail Medical Store Automated Insulin Delivery (AID) Market by Value
4.2.11 Europe Health Centre Automated Insulin Delivery (AID) Market by Value
4.2.12 Europe Automated Insulin Delivery (AID) Market by Countries
4.2.13 Germany Automated Insulin Delivery (AID) Market by Value
4.2.14 France Automated Insulin Delivery (AID) Market by Value
4.2.15 UK Automated Insulin Delivery (AID) Market by Value
4.2.16 Italy Automated Insulin Delivery (AID) Market by Value
4.2.17 Spain Automated Insulin Delivery (AID) Market by Value
4.3 Asia Pacific Automated Insulin Delivery (AID) Market: An Analysis
4.3.1 Asia Pacific Automated Insulin Delivery (AID) Market by Value
4.3.2 Asia Pacific Automated Insulin Delivery (AID) Market by Devices
4.3.3 Asia Pacific Hybrid Closed Loop AID Market by Value
4.3.4 Asia Pacific Fully Closed Loop AID Market by Value
4.3.5 Asia Pacific Automated Insulin Delivery (AID) Market by Diabetes
4.3.6 Asia Pacific Automated Insulin Delivery (AID) Type I Diabetes Market by Value
4.3.7 Asia Pacific Automated Insulin Delivery (AID) Type II Diabetes Market by Value
4.3.8 Asia Pacific Automated Insulin Delivery (AID) Market by End User
4.3.9 Asia Pacific Hospital Automated Insulin Delivery (AID) Market by Value
4.3.10 Asia Pacific Retail Medical Store Automated Insulin Delivery (AID) Market by Value
4.3.11 Asia Pacific Health Centre Automated Insulin Delivery (AID) Market by Value
4.3.12 Asia Pacific Automated Insulin Delivery (AID) Market by Countries
4.3.13 Japan Automated Insulin Delivery (AID) Market by Value
4.3.14 China Automated Insulin Delivery (AID) Market by Value
4.3.15 India Automated Insulin Delivery (AID) Market by Value
4.3.16 Australia Automated Insulin Delivery (AID) Market by Value
4.3.17 South Korea Automated Insulin Delivery (AID) Market by Value
4.4 Latin America Automated Insulin Delivery (AID) Market: An Analysis
4.4.1 Latin America Automated Insulin Delivery (AID) Market by Value
4.5 Middle East & Africa Automated Insulin Delivery (AID) Market: An Analysis
4.5.1 Middle East & Africa Automated Insulin Delivery (AID) Market by Value
5. COVID-19
5.1 Impact of Covid-19
5.2 Response of Industry to Covid-19
5.3 Variation in Organic Traffic
6. MARKET DYNAMICS
6.1 Growth Drivers
6.1.1 Increasing Diabetic Population
6.1.2 Growth in Geriatric Population
6.1.3 Surging Obese Population
6.1.4 Rising Global Healthcare Expenditure
6.1.5 Change in Lifestyle
6.2 Challenges
6.2.1 Oral Insulin
6.2.2 Regulatory Compliance Problem
6.3 Market Trends
6.3.1 Rising Adoption of Wearable Healthcare Devices
6.3.2 Novel Product Launches
7. COMPETITIVE LANDSCAPE
7.1 Global Automated Insulin Delivery (AID) Market Players: A Financial Comparison
7.2 Global Insulin Pump Installed Base Unit Market Share by Players
7.3 Global Insulin Pump Sales Market Share by Players
8. COMPANY PROFILES
8.1 Novo Nordisk
8.1.1 Business Overview
8.1.2 Financial Overview
8.1.3 Business Strategy
8.2 Medtronic Plc
8.2.1 Business Overview
8.2.2 Financial Overview
8.2.3 Business Strategy
8.3 Biocon
8.3.1 Business Overview
8.3.2 Financial Overview
8.3.3 Business Strategy
8.4 Eli Lilly and Company
8.4.1 Business Overview
8.4.2 Financial Overview
8.4.3 Business Strategy
LIST OF FIGURES
Figure 1: Types of Insulin Delivery Devices
Figure 2: Different Insulin Delivery Devices
Figure 3: Important Algorithms Proposed for Artificial Pancreas System
Figure 4: Automated Insulin Delivery Segmentation
Figure 5: Global Automated Insulin Delivery (AID) Market by Value; 2018-2019 (US$ Billion)
Figure 6: Global Automated Insulin Delivery (AID) Market by Value; 2020-2024 (US$ Billion)
Figure 7: Global Automated Insulin Delivery (AID) Market by Device; 2019 (Percentage, %)
Figure 8: Global Automated Insulin Delivery (AID) Market by Diabetes; 2019 (Percentage, %)
Figure 9: Global Automated Insulin Delivery (AID) Market by End-User; 2019 (Percentage, %)
Figure 10: Global Automated Insulin Delivery (AID) Market by Region; 2019 (Percentage, %)
Figure 11: Global Hybrid Closed Loop AID Market by Value; 2018-2019 (US$ Million)
Figure 12: Global Hybrid Closed Loop AID Market by Value; 2020-2024 (US$ Million)
Figure 13: Global Fully Closed Loop AID Market by Value; 2018-2019 (US$ Million)
Figure 14: Global Fully Closed Loop AID Market by Value; 2020-2024 (US$ Million)
Figure 15: Global Automated Insulin (AID) Delivery Type I Diabetes Market by Value; 2018-2019 (US$ Million)
Figure 16: Global Automated Insulin Delivery (AID) Type I Diabetes Market by Value; 2020-2024 (US$ Million)
Figure 17: Global Automated Insulin Delivery (AID) Type II Diabetes Market by Value; 2018-2019 (US$ Million)
Figure 18: Global Automated Insulin Delivery (AID) Type II Diabetes Market by Value; 2020-2024 (US$ Million)
Figure 19: Global Hospital Automated Insulin Delivery (AID) Market by Value; 2018-2019 (US$ Million)
Figure 20: Global Hospital Automated Insulin Delivery (AID) Market by Value; 2020-2024 (US$ Million)
Figure 21: Global Retail Medical Store Automated Insulin Delivery (AID) Market by Value; 2018-2019 (US$ Million)
Figure 22: Global Retail Medical Store Automated Insulin Delivery (AID) Market by Value; 2020-2024 (US$ Million)
Figure 23: Global Health Centre Automated Insulin Delivery (AID) Market by Value; 2018-2019 (US$ Million)
Figure 24: Global Health Centre Automated Insulin Delivery (AID) Market by Value; 2020-2024 (US$ Million)
Figure 25: North America Automated Insulin Delivery (AID) Market by Value; 2018-2019 (US$ Million)
Figure 26: North America Automated Insulin Delivery (AID) Market by Value; 2020-2024 (US$ Million)
Figure 27: North America Automated Insulin Delivery (AID) Market by Device; 2019 (Percentage, %)
Figure 28: North America Hybrid Closed Loop AID Market by Value; 2018-2019 (US$ Million)
Figure 29: North America Hybrid Closed Loop AID Market by Value; 2020-2024 (US$ Million)
Figure 30: North America Fully Closed Loop AID Market by Value; 2018-2019 (US$ Million)
Figure 31: North America Fully Closed Loop AID Market by Value; 2020-2024 (US$ Million)
Figure 32: North America Automated Insulin Delivery (AID) Market by Diabetes; 2019 (Percentage, %)
Figure 33: North America Automated Insulin Delivery (AID) Type I Diabetes Market by Value; 2018-2019 (US$ Million)
Figure 34: North America Automated Insulin Delivery (AID) Type I Diabetes Market by Value; 2020-2024 (US$ Million)
Figure 35: North America Automated Insulin Delivery (AID) Type II Diabetes Market by Value; 2018-2019 (US$ Million)
Figure 36: North America Automated Insulin Delivery (AID) Type II Diabetes Market by Value; 2020-2024 (US$ Million)
Figure 37: North America Automated Insulin Delivery (AID) Market by End User; 2019 (Percentage, %)
Figure 38: North America Hospital Automated Insulin Delivery (AID) Market by Value; 2018-2019 (US$ Million)
Figure 39: North America Hospital Automated Insulin Delivery (AID) Market by Value; 2020-2024 (US$ Million)
Figure 40: North America Retail Medical Store Automated Insulin Delivery (AID) Market by Value; 2018-2019 (US$ Million)
Figure 41: North America Retail Medical Store Automated Insulin Delivery (AID) Market by Value; 2020-2024 (US$ Million)
Figure 42: North America Health Centre Automated Insulin Delivery (AID) Market by Value; 2018-2019 (US$ Million)
Figure 43: North America Health Centre Automated Insulin Delivery (AID) Market by Value; 2020-2024 (US$ Million)
Figure 44: North America Automated Insulin Delivery (AID) Market by Countries; 2019 (Percentage, %)
Figure 45: The US Automated Insulin Delivery (AID) Market by Value; 2018-2019 (US$ Million)
Figure 46: The US Automated Insulin Delivery (AID) Market by Value; 2020-2024 (US$ Million)
Figure 47: Canada Automated Insulin Delivery (AID) Market by Value; 2018-2019 (US$ Million)
Figure 48: Canada Automated Insulin Delivery (AID) Market by Value; 2020-2024 (US$ Million)
Figure 49: Europe Automated Insulin Delivery (AID) Market by Value; 2018-2019 (US$ Million)
Figure 50: Europe Automated Insulin Delivery (AID) Market by Value; 2020-2024 (US$ Million)
Figure 51: Europe Automated Insulin Delivery (AID) Market by Devices; 2019 (Percentage, %)
Figure 52: Europe Hybrid Closed Loop AID Market by Value; 2018-2019 (US$ Million)
Figure 53: Europe Hybrid Closed Loop AID Market by Value; 2020-2024 (US$ Million)
Figure 54: Europe Fully Closed Loop AID Market by Value; 2018-2019 (US$ Million)
Figure 55: Europe Fully Closed Loop AID Market by Value; 2020-2024 (US$ Million)
Figure 56: Europe Automated Insulin Delivery (AID) Market by Diabetes; 2019 (Percentage, %)
Figure 57: Europe Automated Insulin Delivery (AID) Type I Diabetes Market by Value; 2018-2019 (US$ Million)
Figure 58: Europe Automated Insulin Delivery (AID) Type I Diabetes Market by Value; 2020-2024 (US$ Million)
Figure 59: Europe Automated Insulin Delivery (AID) Type II Diabetes Market by Value; 2018-2019 (US$ Million)
Figure 60: Europe Automated Insulin Delivery (AID) Type II Diabetes Market by Value; 2020-2024 (US$ Million)
Figure 61: Europe Automated Insulin Delivery (AID) Market by End User; 2019 (Percentage, %)
Figure 62: Europe Hospital Automated Insulin Delivery (AID) Market by Value; 2018-2019 (US$ Million)
Figure 63: Europe Hospital Automated Insulin Delivery (AID) Market by Value; 2020-2024 (US$ Million)
Figure 64: Europe Retail Medical Store Automated Insulin Delivery (AID) Market by Value; 2018-2019 (US$ Million)
Figure 65: Europe Retail Medical Store Automated Insulin Delivery (AID) Market by Value; 2020-2024 (US$ Million)
Figure 66: Europe Health Centre Automated Insulin Delivery (AID) Market by Value; 2018-2019 (US$ Million)
Figure 67: Europe Health Centre Automated Insulin Delivery (AID) Market by Value; 2020-2024 (US$ Million)
Figure 68: Europe Automated Insulin Delivery (AID) Market by Countries; 2019 (Percentage, %)
Figure 69: Germany Automated Insulin Delivery (AID) Market by Value; 2018-2019 (US$ Million)
Figure 70: Germany Automated Insulin Delivery (AID) Market by Value; 2020-2024 (US$ Million)
Figure 71: France Automated Insulin Delivery (AID) Market by Value; 2018-2019 (US$ Million)
Figure 72: France Automated Insulin Delivery (AID) Market by Value; 2020-2024 (US$ Million)
Figure 73: UK Automated Insulin Delivery (AID) Market by Value; 2018-2019 (US$ Million)
Figure 74: UK Automated Insulin Delivery (AID) Market by Value; 2020-2024 (US$ Million)
Figure 75: Italy Automated Insulin Delivery (AID) Market by Value; 2018-2019 (US$ Million)
Figure 76: Italy Automated Insulin Delivery (AID) Market by Value; 2020-2024 (US$ Million)
Figure 77: Spain Automated Insulin Delivery (AID) Market by Value; 2018-2019 (US$ Million)
Figure 78: Spain Automated Insulin Delivery (AID) Market by Value; 2020-2024 (US$ Million)
Figure 79: Asia Pacific Automated Insulin Delivery (AID) Market by Value; 2018-2019 (US$ Million)
Figure 80: Asia Pacific Automated Insulin Delivery (AID) Market by Value; 2020-2024 (US$ Million)
Figure 81: Asia Pacific Automated Insulin Delivery (AID) Market by Devices; 2019 (Percentage, %)
Figure 82: Asia Pacific Hybrid Closed Loop AID Market by Value; 2018-2019 (US$ Million)
Figure 83: Asia Pacific Hybrid Closed Loop AID Market by Value; 2020-2024 (US$ Million)
Figure 84: Asia Pacific Fully Closed Loop AID Market by Value; 2018-2019 (US$ Million)
Figure 85: Asia Pacific Fully Closed Loop AID Market by Value; 2020-2024 (US$ Million)
Figure 86: Asia Pacific Automated Insulin Delivery (AID) Market by Diabetes; 2019 (Percentage, %)
Figure 87: Asia Pacific Automated Insulin Delivery (AID) Type I Diabetes Market by Value; 2018-2019 (US$ Million)
Figure 88: Asia Pacific Automated Insulin Delivery Type I Diabetes (AID) Market by Value; 2020-2024 (US$ Million)
Figure 89: Asia Pacific Automated Insulin Delivery (AID) Type II Diabetes Market by Value; 2018-2019 (US$ Million)
Figure 90: Asia Pacific Automated Insulin Delivery (AID) Type II Diabetes Market by Value; 2020-2024 (US$ Million)
Figure 91: Asia Pacific Automated Insulin Delivery (AID) Market by End User; 2019 (Percentage, %)
Figure 92: Asia Pacific Hospital Automated Insulin Delivery (AID) Market by Value; 2018-2019 (US$ Million)
Figure 93: Asia Pacific Hospital Automated Insulin Delivery (AID) Market by Value; 2020-2024 (US$ Million)
Figure 94: Asia Pacific Retail Medical Store Automated Insulin Delivery (AID) Market by Value; 2018-2019 (US$ Million)
Figure 95: Asia Pacific Retail Medical Store Automated Insulin Delivery (AID) Market by Value; 2020-2024 (US$ Million)
Figure 96: Asia Pacific Health Centre Automated Insulin Delivery (AID) Market by Value; 2018-2019 (US$ Million)
Figure 97: Asia Pacific Health Centre Automated Insulin Delivery (AID) Market by Value; 2020-2024 (US$ Million)
Figure 98: Asia Pacific Automated Insulin Delivery (AID) Market by Countries; 2019 (Percentage, %)
Figure 99: Japan Automated Insulin Delivery (AID) Market by Value; 2018-2019 (US$ Million)
Figure 100: Japan Automated Insulin Delivery (AID) Market by Value; 2020-2024 (US$ Million)
Figure 101: China Automated Insulin Delivery (AID) Market by Value; 2018-2019 (US$ Million)
Figure 102: China Automated Insulin Delivery (AID) Market by Value; 2020-2024 (US$ Million)
Figure 103: India Automated Insulin Delivery (AID) Market by Value; 2018-2019 (US$ Million)
Figure 104: India Automated Insulin Delivery (AID) Market by Value; 2020-2024 (US$ Million)
Figure 105: Australia Automated Insulin Delivery (AID) Market by Value; 2018-2019 (US$ Million)
Figure 106: Australia Automated Insulin Delivery (AID) Market by Value; 2020-2024 (US$ Million)
Figure 107: South Korea Automated Insulin Delivery (AID) Market by Value; 2018-2019 (US$ Million)
Figure 108: South Korea Automated Insulin Delivery (AID) Market by Value; 2020-2024 (US$ Million)
Figure 109: Latin America Automated Insulin Delivery (AID) Market by Value; 2018-2019 (US$ Million)
Figure 110: Latin America Automated Insulin Delivery (AID) Market by Value; 2020-2024 (US$ Million)
Figure 111: Middle East & Africa Automated Insulin Delivery (AID) Market by Value; 2018-2019 (US$ Million)
Figure 112: Middle East & Africa Automated Insulin Delivery (AID) Market by Value; 2020-2024 (US$ Million)
Figure 113: Variation in Organic Traffic due to COVID-19 (2020)
Figure 114: Global Diabetic Population; 2019-2045 (Million)
Figure 115: Global Population Proportion Above 65 Years of Age; 2019-2030 (Million)
Figure 116: Global Prevalence of Obesity; 2008-2025 (Billion)
Figure 117: Global Healthcare Expenditure; 2017-2022 (US$ Trillion)
Figure 118: Global Wearable Healthcare Devices Market; 2020-2024 (US$ Billion)
Figure 119: Global Insulin Pump Installed Base Unit Market Share by Players; 2019 (Percentage, %)
Figure 120: Global Insulin Pump Sales Market Share by Players; 2019 (Percentage, %)
Figure 121: Novo Nordisk Net Sales; 2015-2019 (US$ Billion)
Figure 122: Novo Nordisk Net Sales by Segment; 2019 (Percentage, %)
Figure 123: Novo Nordisk Net Sales by Region; 2019 (Percentage, %)
Figure 124: Medtronic Plc Net Sales; 2015-2019 (US$ Billion)
Figure 125: Medtronic Plc Net Sales by Segments; 2019 (Percentage, %)
Figure 126: Medtronic Plc Net Sales by Region; 2019 (Percentage, %)
Figure 127: Biocon Revenue; 2016-2020 (US$ Million)
Figure 128: Biocon Revenue by Segment; 2020 (Percentage, %)
Figure 129: Biocon Revenue by Region; 2020 (Percentage, %)
Figure 130: Eli Lilly and Company Revenue; 2015-2019 (US$ Billion)
Figure 131: Eli Lilly and Company Revenue by Product; 2019 (Percentage, %)
Figure 132: Eli Lilly and Company Revenue by Region; 2019 (Percentage, %)
Table 1: Comparison of MPC, PID, and Fuzzy-Logic Algorithms
Table 2: Global Automated Insulin Delivery (AID) Market Players: A Financial Comparison; 2019/2020
Figure 1: Types of Insulin Delivery Devices
Figure 2: Different Insulin Delivery Devices
Figure 3: Important Algorithms Proposed for Artificial Pancreas System
Figure 4: Automated Insulin Delivery Segmentation
Figure 5: Global Automated Insulin Delivery (AID) Market by Value; 2018-2019 (US$ Billion)
Figure 6: Global Automated Insulin Delivery (AID) Market by Value; 2020-2024 (US$ Billion)
Figure 7: Global Automated Insulin Delivery (AID) Market by Device; 2019 (Percentage, %)
Figure 8: Global Automated Insulin Delivery (AID) Market by Diabetes; 2019 (Percentage, %)
Figure 9: Global Automated Insulin Delivery (AID) Market by End-User; 2019 (Percentage, %)
Figure 10: Global Automated Insulin Delivery (AID) Market by Region; 2019 (Percentage, %)
Figure 11: Global Hybrid Closed Loop AID Market by Value; 2018-2019 (US$ Million)
Figure 12: Global Hybrid Closed Loop AID Market by Value; 2020-2024 (US$ Million)
Figure 13: Global Fully Closed Loop AID Market by Value; 2018-2019 (US$ Million)
Figure 14: Global Fully Closed Loop AID Market by Value; 2020-2024 (US$ Million)
Figure 15: Global Automated Insulin (AID) Delivery Type I Diabetes Market by Value; 2018-2019 (US$ Million)
Figure 16: Global Automated Insulin Delivery (AID) Type I Diabetes Market by Value; 2020-2024 (US$ Million)
Figure 17: Global Automated Insulin Delivery (AID) Type II Diabetes Market by Value; 2018-2019 (US$ Million)
Figure 18: Global Automated Insulin Delivery (AID) Type II Diabetes Market by Value; 2020-2024 (US$ Million)
Figure 19: Global Hospital Automated Insulin Delivery (AID) Market by Value; 2018-2019 (US$ Million)
Figure 20: Global Hospital Automated Insulin Delivery (AID) Market by Value; 2020-2024 (US$ Million)
Figure 21: Global Retail Medical Store Automated Insulin Delivery (AID) Market by Value; 2018-2019 (US$ Million)
Figure 22: Global Retail Medical Store Automated Insulin Delivery (AID) Market by Value; 2020-2024 (US$ Million)
Figure 23: Global Health Centre Automated Insulin Delivery (AID) Market by Value; 2018-2019 (US$ Million)
Figure 24: Global Health Centre Automated Insulin Delivery (AID) Market by Value; 2020-2024 (US$ Million)
Figure 25: North America Automated Insulin Delivery (AID) Market by Value; 2018-2019 (US$ Million)
Figure 26: North America Automated Insulin Delivery (AID) Market by Value; 2020-2024 (US$ Million)
Figure 27: North America Automated Insulin Delivery (AID) Market by Device; 2019 (Percentage, %)
Figure 28: North America Hybrid Closed Loop AID Market by Value; 2018-2019 (US$ Million)
Figure 29: North America Hybrid Closed Loop AID Market by Value; 2020-2024 (US$ Million)
Figure 30: North America Fully Closed Loop AID Market by Value; 2018-2019 (US$ Million)
Figure 31: North America Fully Closed Loop AID Market by Value; 2020-2024 (US$ Million)
Figure 32: North America Automated Insulin Delivery (AID) Market by Diabetes; 2019 (Percentage, %)
Figure 33: North America Automated Insulin Delivery (AID) Type I Diabetes Market by Value; 2018-2019 (US$ Million)
Figure 34: North America Automated Insulin Delivery (AID) Type I Diabetes Market by Value; 2020-2024 (US$ Million)
Figure 35: North America Automated Insulin Delivery (AID) Type II Diabetes Market by Value; 2018-2019 (US$ Million)
Figure 36: North America Automated Insulin Delivery (AID) Type II Diabetes Market by Value; 2020-2024 (US$ Million)
Figure 37: North America Automated Insulin Delivery (AID) Market by End User; 2019 (Percentage, %)
Figure 38: North America Hospital Automated Insulin Delivery (AID) Market by Value; 2018-2019 (US$ Million)
Figure 39: North America Hospital Automated Insulin Delivery (AID) Market by Value; 2020-2024 (US$ Million)
Figure 40: North America Retail Medical Store Automated Insulin Delivery (AID) Market by Value; 2018-2019 (US$ Million)
Figure 41: North America Retail Medical Store Automated Insulin Delivery (AID) Market by Value; 2020-2024 (US$ Million)
Figure 42: North America Health Centre Automated Insulin Delivery (AID) Market by Value; 2018-2019 (US$ Million)
Figure 43: North America Health Centre Automated Insulin Delivery (AID) Market by Value; 2020-2024 (US$ Million)
Figure 44: North America Automated Insulin Delivery (AID) Market by Countries; 2019 (Percentage, %)
Figure 45: The US Automated Insulin Delivery (AID) Market by Value; 2018-2019 (US$ Million)
Figure 46: The US Automated Insulin Delivery (AID) Market by Value; 2020-2024 (US$ Million)
Figure 47: Canada Automated Insulin Delivery (AID) Market by Value; 2018-2019 (US$ Million)
Figure 48: Canada Automated Insulin Delivery (AID) Market by Value; 2020-2024 (US$ Million)
Figure 49: Europe Automated Insulin Delivery (AID) Market by Value; 2018-2019 (US$ Million)
Figure 50: Europe Automated Insulin Delivery (AID) Market by Value; 2020-2024 (US$ Million)
Figure 51: Europe Automated Insulin Delivery (AID) Market by Devices; 2019 (Percentage, %)
Figure 52: Europe Hybrid Closed Loop AID Market by Value; 2018-2019 (US$ Million)
Figure 53: Europe Hybrid Closed Loop AID Market by Value; 2020-2024 (US$ Million)
Figure 54: Europe Fully Closed Loop AID Market by Value; 2018-2019 (US$ Million)
Figure 55: Europe Fully Closed Loop AID Market by Value; 2020-2024 (US$ Million)
Figure 56: Europe Automated Insulin Delivery (AID) Market by Diabetes; 2019 (Percentage, %)
Figure 57: Europe Automated Insulin Delivery (AID) Type I Diabetes Market by Value; 2018-2019 (US$ Million)
Figure 58: Europe Automated Insulin Delivery (AID) Type I Diabetes Market by Value; 2020-2024 (US$ Million)
Figure 59: Europe Automated Insulin Delivery (AID) Type II Diabetes Market by Value; 2018-2019 (US$ Million)
Figure 60: Europe Automated Insulin Delivery (AID) Type II Diabetes Market by Value; 2020-2024 (US$ Million)
Figure 61: Europe Automated Insulin Delivery (AID) Market by End User; 2019 (Percentage, %)
Figure 62: Europe Hospital Automated Insulin Delivery (AID) Market by Value; 2018-2019 (US$ Million)
Figure 63: Europe Hospital Automated Insulin Delivery (AID) Market by Value; 2020-2024 (US$ Million)
Figure 64: Europe Retail Medical Store Automated Insulin Delivery (AID) Market by Value; 2018-2019 (US$ Million)
Figure 65: Europe Retail Medical Store Automated Insulin Delivery (AID) Market by Value; 2020-2024 (US$ Million)
Figure 66: Europe Health Centre Automated Insulin Delivery (AID) Market by Value; 2018-2019 (US$ Million)
Figure 67: Europe Health Centre Automated Insulin Delivery (AID) Market by Value; 2020-2024 (US$ Million)
Figure 68: Europe Automated Insulin Delivery (AID) Market by Countries; 2019 (Percentage, %)
Figure 69: Germany Automated Insulin Delivery (AID) Market by Value; 2018-2019 (US$ Million)
Figure 70: Germany Automated Insulin Delivery (AID) Market by Value; 2020-2024 (US$ Million)
Figure 71: France Automated Insulin Delivery (AID) Market by Value; 2018-2019 (US$ Million)
Figure 72: France Automated Insulin Delivery (AID) Market by Value; 2020-2024 (US$ Million)
Figure 73: UK Automated Insulin Delivery (AID) Market by Value; 2018-2019 (US$ Million)
Figure 74: UK Automated Insulin Delivery (AID) Market by Value; 2020-2024 (US$ Million)
Figure 75: Italy Automated Insulin Delivery (AID) Market by Value; 2018-2019 (US$ Million)
Figure 76: Italy Automated Insulin Delivery (AID) Market by Value; 2020-2024 (US$ Million)
Figure 77: Spain Automated Insulin Delivery (AID) Market by Value; 2018-2019 (US$ Million)
Figure 78: Spain Automated Insulin Delivery (AID) Market by Value; 2020-2024 (US$ Million)
Figure 79: Asia Pacific Automated Insulin Delivery (AID) Market by Value; 2018-2019 (US$ Million)
Figure 80: Asia Pacific Automated Insulin Delivery (AID) Market by Value; 2020-2024 (US$ Million)
Figure 81: Asia Pacific Automated Insulin Delivery (AID) Market by Devices; 2019 (Percentage, %)
Figure 82: Asia Pacific Hybrid Closed Loop AID Market by Value; 2018-2019 (US$ Million)
Figure 83: Asia Pacific Hybrid Closed Loop AID Market by Value; 2020-2024 (US$ Million)
Figure 84: Asia Pacific Fully Closed Loop AID Market by Value; 2018-2019 (US$ Million)
Figure 85: Asia Pacific Fully Closed Loop AID Market by Value; 2020-2024 (US$ Million)
Figure 86: Asia Pacific Automated Insulin Delivery (AID) Market by Diabetes; 2019 (Percentage, %)
Figure 87: Asia Pacific Automated Insulin Delivery (AID) Type I Diabetes Market by Value; 2018-2019 (US$ Million)
Figure 88: Asia Pacific Automated Insulin Delivery Type I Diabetes (AID) Market by Value; 2020-2024 (US$ Million)
Figure 89: Asia Pacific Automated Insulin Delivery (AID) Type II Diabetes Market by Value; 2018-2019 (US$ Million)
Figure 90: Asia Pacific Automated Insulin Delivery (AID) Type II Diabetes Market by Value; 2020-2024 (US$ Million)
Figure 91: Asia Pacific Automated Insulin Delivery (AID) Market by End User; 2019 (Percentage, %)
Figure 92: Asia Pacific Hospital Automated Insulin Delivery (AID) Market by Value; 2018-2019 (US$ Million)
Figure 93: Asia Pacific Hospital Automated Insulin Delivery (AID) Market by Value; 2020-2024 (US$ Million)
Figure 94: Asia Pacific Retail Medical Store Automated Insulin Delivery (AID) Market by Value; 2018-2019 (US$ Million)
Figure 95: Asia Pacific Retail Medical Store Automated Insulin Delivery (AID) Market by Value; 2020-2024 (US$ Million)
Figure 96: Asia Pacific Health Centre Automated Insulin Delivery (AID) Market by Value; 2018-2019 (US$ Million)
Figure 97: Asia Pacific Health Centre Automated Insulin Delivery (AID) Market by Value; 2020-2024 (US$ Million)
Figure 98: Asia Pacific Automated Insulin Delivery (AID) Market by Countries; 2019 (Percentage, %)
Figure 99: Japan Automated Insulin Delivery (AID) Market by Value; 2018-2019 (US$ Million)
Figure 100: Japan Automated Insulin Delivery (AID) Market by Value; 2020-2024 (US$ Million)
Figure 101: China Automated Insulin Delivery (AID) Market by Value; 2018-2019 (US$ Million)
Figure 102: China Automated Insulin Delivery (AID) Market by Value; 2020-2024 (US$ Million)
Figure 103: India Automated Insulin Delivery (AID) Market by Value; 2018-2019 (US$ Million)
Figure 104: India Automated Insulin Delivery (AID) Market by Value; 2020-2024 (US$ Million)
Figure 105: Australia Automated Insulin Delivery (AID) Market by Value; 2018-2019 (US$ Million)
Figure 106: Australia Automated Insulin Delivery (AID) Market by Value; 2020-2024 (US$ Million)
Figure 107: South Korea Automated Insulin Delivery (AID) Market by Value; 2018-2019 (US$ Million)
Figure 108: South Korea Automated Insulin Delivery (AID) Market by Value; 2020-2024 (US$ Million)
Figure 109: Latin America Automated Insulin Delivery (AID) Market by Value; 2018-2019 (US$ Million)
Figure 110: Latin America Automated Insulin Delivery (AID) Market by Value; 2020-2024 (US$ Million)
Figure 111: Middle East & Africa Automated Insulin Delivery (AID) Market by Value; 2018-2019 (US$ Million)
Figure 112: Middle East & Africa Automated Insulin Delivery (AID) Market by Value; 2020-2024 (US$ Million)
Figure 113: Variation in Organic Traffic due to COVID-19 (2020)
Figure 114: Global Diabetic Population; 2019-2045 (Million)
Figure 115: Global Population Proportion Above 65 Years of Age; 2019-2030 (Million)
Figure 116: Global Prevalence of Obesity; 2008-2025 (Billion)
Figure 117: Global Healthcare Expenditure; 2017-2022 (US$ Trillion)
Figure 118: Global Wearable Healthcare Devices Market; 2020-2024 (US$ Billion)
Figure 119: Global Insulin Pump Installed Base Unit Market Share by Players; 2019 (Percentage, %)
Figure 120: Global Insulin Pump Sales Market Share by Players; 2019 (Percentage, %)
Figure 121: Novo Nordisk Net Sales; 2015-2019 (US$ Billion)
Figure 122: Novo Nordisk Net Sales by Segment; 2019 (Percentage, %)
Figure 123: Novo Nordisk Net Sales by Region; 2019 (Percentage, %)
Figure 124: Medtronic Plc Net Sales; 2015-2019 (US$ Billion)
Figure 125: Medtronic Plc Net Sales by Segments; 2019 (Percentage, %)
Figure 126: Medtronic Plc Net Sales by Region; 2019 (Percentage, %)
Figure 127: Biocon Revenue; 2016-2020 (US$ Million)
Figure 128: Biocon Revenue by Segment; 2020 (Percentage, %)
Figure 129: Biocon Revenue by Region; 2020 (Percentage, %)
Figure 130: Eli Lilly and Company Revenue; 2015-2019 (US$ Billion)
Figure 131: Eli Lilly and Company Revenue by Product; 2019 (Percentage, %)
Figure 132: Eli Lilly and Company Revenue by Region; 2019 (Percentage, %)
Table 1: Comparison of MPC, PID, and Fuzzy-Logic Algorithms
Table 2: Global Automated Insulin Delivery (AID) Market Players: A Financial Comparison; 2019/2020
